What This 'Standout Performance' Means For Broader Medtech

The 'Standout Performance' That Could Save Thermo Fisher, Danaher And Others

Licensing

09:42 AM ET 07/23/2026

Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm. The "standout performance" from Thermo Fisher Scientific's (TMO) analytical instruments business, coupled with promising related news from Danaher (DHR) and Sartorius, suggest "an instrument recovery theme is emerging," RBC Capital Markets analyst Dan Leonard said in a report. In…

What This 'Standout Performance' Means For Broader Medtech

Other newsrooms on this story

Related reading

Thermo Fisher Points to Improving End-Market Activity - Thermo Fisher…

Danaher gives investors reasons to stick around, sending beaten-up shares flying

An under-the-radar medical device stock with 20% upside, according to the charts

Danaher is tapping the M&A well yet again. But we might have had enough

Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing,…

Jim Cramer has faith in Danaher's turnaround as life sciences comes back to life